Federated Hermes Inc. Decreases Stock Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)

Federated Hermes Inc. trimmed its holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) by 2.2% during the fourth quarter, HoldingsChannel reports. The firm owned 595,692 shares of the company’s stock after selling 13,094 shares during the period. Federated Hermes Inc.’s holdings in Atea Pharmaceuticals were worth $1,817,000 at the end of the most recent reporting period.

A number of other institutional investors have also bought and sold shares of AVIR. BML Capital Management LLC raised its position in shares of Atea Pharmaceuticals by 114.6% during the 3rd quarter. BML Capital Management LLC now owns 4,800,000 shares of the company’s stock valued at $14,400,000 after buying an additional 2,563,761 shares during the period. Stonepine Capital Management LLC raised its position in shares of Atea Pharmaceuticals by 128.7% during the 3rd quarter. Stonepine Capital Management LLC now owns 1,720,000 shares of the company’s stock valued at $5,160,000 after buying an additional 967,912 shares during the period. Newtyn Management LLC raised its position in shares of Atea Pharmaceuticals by 348.4% during the 3rd quarter. Newtyn Management LLC now owns 400,000 shares of the company’s stock valued at $1,200,000 after buying an additional 310,803 shares during the period. Sectoral Asset Management Inc. raised its position in shares of Atea Pharmaceuticals by 19.7% during the 3rd quarter. Sectoral Asset Management Inc. now owns 600,461 shares of the company’s stock valued at $1,801,000 after buying an additional 98,924 shares during the period. Finally, GSA Capital Partners LLP raised its position in shares of Atea Pharmaceuticals by 41.9% during the 3rd quarter. GSA Capital Partners LLP now owns 278,286 shares of the company’s stock valued at $835,000 after buying an additional 82,208 shares during the period. 86.67% of the stock is owned by hedge funds and other institutional investors.

Atea Pharmaceuticals Stock Performance

AVIR stock opened at $3.71 on Monday. The firm has a market cap of $312.27 million, a PE ratio of -2.26 and a beta of 0.16. The firm’s 50 day moving average price is $3.96 and its 200-day moving average price is $3.53. Atea Pharmaceuticals, Inc. has a one year low of $2.77 and a one year high of $5.19.

Atea Pharmaceuticals (NASDAQ:AVIR) last released its quarterly earnings results on Wednesday, February 28th. The company reported ($0.47) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.03). Equities research analysts predict that Atea Pharmaceuticals, Inc. will post -2.76 EPS for the current fiscal year.

Insider Buying and Selling at Atea Pharmaceuticals

In other Atea Pharmaceuticals news, insider Andrea Corcoran sold 15,843 shares of the business’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $3.84, for a total value of $60,837.12. Following the sale, the insider now owns 670,208 shares of the company’s stock, valued at $2,573,598.72. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Atea Pharmaceuticals news, CAO Wayne Foster sold 12,477 shares of the business’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $3.84, for a total value of $47,911.68. Following the sale, the chief accounting officer now owns 20,857 shares of the company’s stock, valued at $80,090.88. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Andrea Corcoran sold 15,843 shares of the business’s stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $3.84, for a total value of $60,837.12. Following the completion of the sale, the insider now directly owns 670,208 shares in the company, valued at approximately $2,573,598.72. The disclosure for this sale can be found here. Insiders have sold a total of 85,230 shares of company stock valued at $327,852 over the last quarter. 14.50% of the stock is owned by company insiders.

Atea Pharmaceuticals Company Profile

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.